Pfizer’s DEI Employment Practices: What the Company’s Own Documents Show — and What They Mean for Employees

Published August 22, 2026 · Last updated August 22, 2026 · By Fett Law — Michigan Employment Discrimination Attorneys

Pfizer Inc. documented four categories of demographic employment practice in its own published reports between 2019 and 2024: vice-president-level representation percentages used as key performance indicators that helped determine the funding of a bonus plan covering more than 40,000 colleagues and leaders; mandatory diverse candidate slates and interview panels for all U.S. job requisitions; numeric 2025 representation goals, including doubling Black and Hispanic representation at the VP level and above; and a fellowship pipeline built around Black, Latino and Native American descent. Similar practices were the basis of IBM’s $17 million False Claims Act settlement with the U.S. Department of Justice in April 2026.

Key facts

Item	Detail
Company	Pfizer Inc. (NYSE: PFE), one of the world’s largest pharmaceutical companies, headquartered in New York with U.S. operations including sites in New York, Connecticut, Missouri, Michigan, North Carolina, Kansas and Puerto Rico
Federal nexus	Substantial federal contractor and supplier. Pfizer’s July 22, 2020 agreement with the U.S. Department of Health and Human Services and the Department of Defense provided for $1.95 billion on receipt of the first 100 million COVID-19 vaccine doses, with options for up to 600 million doses; a June 2022 agreement added roughly $3.2 billion for 105 million doses; the U.S. Army contracted for hundreds of millions of additional doses for international donation. Pfizer products are also supplied to the Department of Veterans Affairs and the Department of Defense through federal supply schedules.
Documents reviewed	12+ company-published documents, 2019–2026: ESG Reports 2020–2022, Impact Reports 2023–2025, the 2021 Annual Review, the March 2024 Racial Equity Assessment, consolidated EEO-1 Reports 2016–2024, and Pfizer’s diversity web pages before and after February 2025
Practices documented	(1) VP-level women and U.S. minority representation percentages used as ESG Scorecard KPIs that were factors in funding the annual short-term incentive plan; (2) mandatory diverse candidate slate and interview panel requirements for all U.S. job requisitions, gated by a pre-offer compliance survey; (3) numeric 2025 “opportunity parity” goals, including raising U.S. minority VP+ representation from 19% to 32% and doubling Black and Hispanic representation; (4) the Breakthrough Fellowship Program, a hiring pipeline built around Black/African American, Latinx/Hispanic and Native American descent
Source-document status	Largely intact — with one exception. Unlike many peers, Pfizer did not scrub its report archive: the 2021 and 2022 ESG Reports, the 2023–2025 Impact Reports, the EEO-1 file and the Racial Equity Assessment all remain on Pfizer’s own servers. The 2020 ESG Report — the edition carrying the most specific representation targets — is no longer reachable at its original Pfizer address; archived copies are preserved and linked in Sources.

Did Pfizer tie bonus funding to diversity targets?

Yes. For the 2022 and 2023 performance years, Pfizer Inc.’s Compensation Committee selected the percentage of vice-president-and-above roles held by women globally and by minorities in the United States as two of the three key performance indicators on its ESG Scorecard — and those KPIs were factors in determining the funding of Pfizer’s annual short-term incentive plan for tens of thousands of colleagues and leaders.

Pfizer described the mechanism in its own ESG report:

“Our ESG strategy is designed by leadership to leverage compensation as a key motivator to hold ourselves accountable. For the 2022 performance year, the Compensation Committee of the Board leveraged the ESG Scorecard, which included three selected social and environmental key performance indicators (KPIs). Those ESG Scorecard KPIs, listed below, were factors in determining the funding of our annual short-term incentive plan (Global Performance Plan [GPP] program) for over 30,000 global colleagues and leaders.”

“We believe these ESG Scorecard KPIs—(i) percentage of Vice President and higher roles held by women (globally), (ii) percentage of Vice President and higher roles held by minorities (U.S.), and (iii) Greenhouse Gas Emissions—are holistic drivers of our future success as a company. The goals set for 2022, as part of the GPP program, were also based on our publicly announced longer term goals in these areas.”

— Pfizer, Environmental, Social & Governance Report Pfizer 2022, p. 47 (source)

The same report records that the Compensation Committee “adopted the ESG Scorecard to tie the funding of our annual short-term incentive plan for over 30,000 global colleagues and leaders, in part, to select social and environmental key performance indicators,” and adds that “the three metrics used in the ESG Scorecard for the short-term annual incentive plan, may also be included in the individual performance goals of executives throughout the organization.”

The next year the same architecture applied to a larger population:

“For the 2023 performance year, the Compensation Committee of the Board selected three social and environmental KPIs for the ESG Scorecard to tie to our annual short-term incentive compensation: 1. Percentage of VP and higher roles held by women (globally) 2. Percentage of VP and higher roles held by minorities (U.S.) 3. Greenhouse Gas Emissions … The ESG Scorecard KPIs were factors in evaluating the funding of our GPP Program for over 40,000 eligible global colleagues and leaders.”

— Pfizer, 2023 Impact Report, p. 23, “Right Incentives” (source). The report’s summary page states plainly: “Over 40K Pfizer leaders have ESG KPIs factored into their compensation.”

In plain terms: two of the three non-financial measures that helped set how much money went into the bonus pool were counts of how many senior roles were held by women and by U.S. minorities. Pfizer’s own framing is that the design was deliberate — compensation as “a key motivator to hold ourselves accountable.” For an employee or applicant, the practical question follows directly: when the number of senior roles held by a demographic group helps determine what a very large group of colleagues is paid, what instructions did that produce for the people making individual hiring and promotion decisions?

Did Pfizer require diverse slates in hiring?

Yes. Beginning in 2022, Pfizer Inc. imposed mandatory diverse candidate slate and interview panel requirements on all U.S. job requisitions, and no offer could be generated until the hiring manager completed a survey confirming the requirements were met. This is described in a report Pfizer commissioned from Covington & Burling LLP and published on its own website in March 2024.

“In 2022, Pfizer implemented mandatory requirements for including a diverse group of applicants on interview slates (the group of candidates being interviewed for open roles) and ensuring that applicants interview with a diverse panel of Pfizer interviewers for all U.S. job requisitions. Pfizer considers a candidate slate or interview panel to be diverse if it includes at least one ethnically diverse individual and at least two genders are represented. This requirement cannot be fulfilled by the same person.”

“Before making a selection decision, hiring managers must complete a survey confirming whether the candidate slate and interview panel diversity requirements have been met… An offer cannot be generated until the hiring manager completes the survey and the recruiter reviews the survey responses for compliance. If the hiring manager indicates that either the interview panel or the candidate slate did not comply with the requirement, they must provide a reason and context for why this occurred. The recruiter may work with the PX team to determine whether an exception can be applied for the noncompliance or if the hiring team needs to identify additional candidates and conduct more interviews.”

— Covington & Burling LLP, A Report to Pfizer Inc. On Its Efforts To Promote Racial Equity, Diversity, and Inclusion, March 2024, p. 14 (source — published by Pfizer at pfizer.com/racialequityassessment)

Two details in that passage matter more than they first appear. The first is scope: not a pilot, not a senior-roles program, but “all U.S. job requisitions.” The second is the gate: the requirement was not aspirational guidance, because the applicant-tracking system would not produce an offer until a compliance survey was completed and reviewed. The report’s own recommendation section asked Pfizer to go further — to “strengthen accountability measures” and add “an additional verification step for recruiters to certify compliance.”

In fairness to Pfizer, the same report states that “candidates are not removed from a slate to meet requirements, only added,” and describes standardized interview questions and a Candidate Evaluation Tool intended to keep assessment on objective criteria. Adding candidates is not the same thing as rejecting one. But a rule that changes who appears on an interview slate, and who sits on the panel that evaluates them, changes the competition — and whether a protected trait actually changed a hiring outcome is a question answered by the people who ran the requisitions.

Did Pfizer set racial and gender representation goals?

Yes. Pfizer Inc. published numeric “opportunity parity” goals for 2025: 47% of vice-president-and-above roles held by women globally, and U.S. minority representation at the VP+ level raised from 19% to 32% — with an explicit commitment to double the Black and Hispanic population at that level. Those same two percentages were the KPIs wired into the bonus plan described above.

“Our 2025 opportunity parity goals: By 2025, we aim to achieve global workforce parity of 47% for women at the VP level and above. By 2025, we aim to achieve parity at the VP+ level for U.S. minorities by increasing our minority representation from 19% to 32% and doubling the underrepresented population of African Americans/Blacks and Hispanics/Latinos.”

— Pfizer, Environmental, Social & Governance Report 2020, p. 22 (published March 10, 2021; footnoted “Revised in June 2020”). This edition is no longer available on pfizer.com; archived copy.

The same report presented the goals as a chart of “VP+ Opportunity Parity Goals” running 2019 → 2020 → 2025 target (global female 33% → 38% → 47%; U.S. minority 19% → 22% → 32%), and Pfizer’s CEO letter described the commitment as setting “concrete goals to address systemic racism and gender equity challenges… particularly focusing on increasing female and U.S. minority representation at leadership levels.”

Pfizer tracked progress against the goals publicly for years afterward. Its 2022 ESG Report reported women at VP+ rising to 43.1% and U.S. minorities to 28.1%; its 2023 Impact Report reported 44.8% and 30.5%, restating the same 2025 goals.

“By 2025, we aspire to achieve global workforce parity of 47% for women at the VP level and above. By 2025, we aspire to achieve workforce parity of 32% for U.S. minorities at the VP level and above, and double the underrepresented population of African Americans / Blacks and Hispanics / Latinos.”

— Pfizer, 2023 Impact Report, “Opportunity Parity” (source)

Pfizer added an important qualifier in the same passage, and it belongs here: “These aspirational goals are not quotas and Pfizer continues to make employment decisions based on qualifications.” That is the company’s position, and no court or agency has held otherwise. What the documents establish is narrower and factual: a numeric demographic target existed, it was published, it carried a date, and the same two percentages helped determine the funding of a bonus plan covering more than 40,000 people. Whether that pressure changed any individual decision is the question that first-hand knowledge answers.

Did Pfizer run programs restricted by race or ethnicity?

Yes. In early 2021 Pfizer Inc. launched the Breakthrough Fellowship Program — described in its own annual review as a nine-year commitment to “increase minority representation,” advancing students and early-career colleagues “of Black/African American, Latinx/Hispanic and Native American descent,” with a goal of 100 Fellows by 2025. The program was a hiring pipeline: 17 of the first cohort of 20 were invited to join Pfizer as full-time colleagues on graduation.

“In early 2021, we launched the Breakthrough Fellowship Program – a nine-year commitment to increase minority representation and enhance our pipeline of diverse leaders. The Breakthrough Fellowship Program, a first-of-its-kind program, works to advance students and early career colleagues of Black/African American, Latinx/Hispanic and Native American descent, with a goal of developing 100 Fellows by 2025.”

“Our first cohort of 20 rising seniors completed the first phase of the program, a 10-week internship, in 2021… We have invited 17 of the first cohort of 20 to join us as full-time colleagues upon graduation in 2022.”

— Pfizer, 2021 Annual Review, “Building Our Next Generation of Leaders” (source)

What made the Fellowship different from a general internship was that the career benefit — a paid summer internship, executive access, an assigned “Equity Mentor,” and in most cases a full-time job offer — ran through a program defined by descent. That is precisely the fourth category in the IBM settlement: training, mentoring and leadership programs whose eligibility is limited on the basis of race.

The program’s eligibility terms were challenged in court. Do No Harm v. Pfizer, Inc. was filed in the U.S. District Court for the Southern District of New York on September 15, 2022, alleging that the Fellowship excluded white and Asian applicants; the complaint quoted an application requirement that candidates “meet the program’s goals of increasing the pipeline for Black/African American, Latino/Hispanic and Native Americans.” In February 2023, Pfizer revised the program’s FAQ to state that applicants are eligible “regardless of whether you are of Black/African American, Latino/Hispanic, or Native American descent.” The district court dismissed on standing grounds; on January 10, 2025 the Second Circuit vacated and remanded, holding the district court had applied the wrong evidentiary standard (Do No Harm v. Pfizer, No. 23-15 (2d Cir. 2025)). The parties filed a joint stipulation of dismissal on January 31, 2025. The allegations were never adjudicated on the merits, and no court found that Pfizer violated any law.

Pfizer also ran leadership-development programs organized through its DEI function — the Connected Leaders Academy, delivered with McKinsey & Company, and the EDGE (Elevating Development, Growth, and Experiences) program, both nomination-based. Pfizer’s published assessment describes EDGE participants as monitored with “a data-driven tool… to confirm that there is equitable participation across all demographic groups,” and states that Pfizer’s nine Enterprise Colleague Resource Groups “are open to all employees.” Those descriptions cut the other way, and belong in an honest account. The Breakthrough Fellowship, before February 2023, is the program whose published eligibility criteria turned on descent.

How Pfizer’s DEI program changed, 2019–2026

Date	Development
2019	Pfizer conducts and publishes its first annual pay equity study; year-end representation reported at 33% women and 19% U.S. minorities at VP and above — the baselines the 2025 goals were set against
June 2020	Pfizer revises and augments its 2025 “opportunity parity” commitments following the summer’s racial-justice protests
Mar. 10, 2021	First standalone ESG Report (2020 reporting year) published, carrying the “VP+ Opportunity Parity Goals” chart and the 19% → 32% / doubling-Black-and-Hispanic commitment
Early 2021	Breakthrough Fellowship Program launched — nine-year commitment, 100 Fellows by 2025, for students of Black/African American, Latinx/Hispanic and Native American descent
2021	DEI strategy “refreshed” and rebuilt around three pillars, to be “measured against 16 outcome metrics and 35 key initiatives” (2021 ESG Report, p. 23)
2022	Mandatory diverse candidate slate and interview panel requirements implemented for all U.S. job requisitions, gated by a pre-offer compliance survey; the Compensation Committee adopts the ESG Scorecard tying short-term incentive funding for 30,000+ colleagues to VP+ women and U.S. minority representation
Sept. 15, 2022	Do No Harm v. Pfizer, Inc. filed in the Southern District of New York challenging the Fellowship’s eligibility criteria (allegations)
Feb. 2023	Pfizer revises the Fellowship FAQ: applicants eligible “regardless of whether you are of Black/African American, Latino/Hispanic, or Native American descent”
2023	ESG Scorecard continues with the same two representation KPIs; the population whose bonus funding they help determine grows to “over 40,000 eligible global colleagues and leaders”
Mar. 2024	Pfizer publishes the Covington & Burling Racial Equity Assessment, the document that describes the mandatory slate and panel requirements in operational detail
Jan. 10, 2025	Second Circuit vacates the dismissal in Do No Harm v. Pfizer and remands
Jan. 21, 2025	Executive Order 14173 revokes Executive Order 11246 and directs that federal contracts include a term requiring the contractor to certify it does not operate DEI programs that violate federal anti-discrimination law
Jan. 31, 2025	Joint stipulation of dismissal filed in Do No Harm v. Pfizer; no merits ruling
Feb. 27, 2025	Pfizer revises its diversity web page, which now reads: “Our culture of diversity, equity and inclusion is based on merit—one where hard work, talent, and contributions drive success, and barriers to opportunity are removed”
May 30, 2025	Consolidated EEO-1 Reports for 2016–2024 posted — Pfizer continues publishing federal workforce-demographic filings
June 2025	2024 Impact Report published: the DEI chapter becomes “Equity for Colleagues,” the 2025 representation targets are gone, and the text describes a “merit-based talent approach”
Apr. 10, 2026	IBM pays $17,077,043 to resolve False Claims Act allegations over DEI practices — the first settlement under DOJ’s Civil Rights Fraud Initiative
June 2026	2025 Impact Report published: “We continue to execute a merit-based talent approach”
Aug. 2026	Pfizer’s report archive remains largely intact; the 2020 ESG Report, carrying the most specific targets, is no longer reachable at its original pfizer.com address

Why these practices matter legally

Title VII of the Civil Rights Act of 1964 prohibits employers from making employment decisions because of race or sex — and it protects every race and both sexes. Two recent Supreme Court decisions sharpened that rule. In Muldrow v. City of St. Louis (2024), the Court held that a plaintiff challenging a discriminatory job transfer need show only some harm from the change in terms or conditions of employment, not a “significant” disadvantage. In Ames v. Ohio Department of Youth Services (decided June 5, 2025), the Court unanimously rejected the “background circumstances” rule that had required majority-group plaintiffs to clear a higher evidentiary bar. Separately, 42 U.S.C. § 1981 prohibits race discrimination in the making and enforcement of contracts — including employment — and carries its own four-year window with no agency filing requirement. (Statutes: Title VII, § 1981; opinions: Muldrow, Ames.)

For federal contractors and suppliers there is a second layer. On April 10, 2026, International Business Machines Corporation paid $17,077,043 to resolve allegations — under the Justice Department’s Civil Rights Fraud Initiative, in DOJ’s first False Claims Act settlement of its kind — that it certified compliance with federal anti-discrimination requirements while operating DEI practices including “a diversity modifier that tied bonus compensation to achieving demographic targets,” altered interview criteria based on race or sex through the use of “diverse interview slates,” “race and sex demographic goals for business units,” and training, mentoring and leadership programs whose eligibility was “limited on the basis of race or sex” (DOJ press release). DOJ stated that “the claims resolved by the United States in the settlement are allegations only and there has been no determination of liability.” The parallel is unusually close here: Pfizer’s own documents describe a version of all four categories.

The nexus fact is straightforward. Pfizer is a substantial federal contractor and supplier — its July 22, 2020 agreement with HHS and the Department of Defense alone provided for $1.95 billion on the first 100 million doses, with options for up to 600 million — and Executive Order 14173, signed January 21, 2025, directs that federal contracts include a term requiring the counterparty “to certify that it does not operate any programs promoting DEI that violate any applicable Federal anti-discrimination laws,” and a term making compliance with federal anti-discrimination law “material to the government’s payment decisions” for False Claims Act purposes (90 FR 8633).

To be clear about what is and is not established: no court or agency has found that Pfizer’s practices violated any law, no DEI-related False Claims Act investigation of Pfizer has been made public, the Do No Harm case ended without any merits ruling, and the IBM settlement itself resolved allegations without any admission of liability. But practices like those documented above — representation percentages feeding bonus funding, mandatory demographic slate and panel requirements, dated numeric representation targets, and a hiring pipeline built around descent — are precisely the categories that can give rise to liability under Title VII and § 1981, and, for companies doing business with the federal government, potential False Claims Act exposure. For the complete framework — the four illegal DEI practice categories and when you can sue — see our guide, Is DEI Illegal? 4 Illegal DEI Practices & When You Can Sue.

Were you affected by these practices at Pfizer?

If you worked at Pfizer Inc. — or applied there — between roughly 2020 and 2025, the documented practices above may have touched your career in ways worth examining:

• You were passed over for a hire or promotion in a U.S. role filled while the mandatory diverse-slate and interview-panel requirements governed the requisition.
• You applied to the Breakthrough Fellowship Program before February 2023 and were screened out, or did not apply because the published eligibility criteria told you it was not for you.
• You were a manager, recruiter, or HR professional with first-hand knowledge of how the slate requirement, the compliance survey, or the VP+ representation targets were actually applied to individual decisions.
• You were a senior leader or colleague inside the bonus plan whose incentive funding depended in part on movement in the demographic composition of VP-and-above roles.
• You were laid off or separated during a Pfizer restructuring and signed a severance agreement without anyone reviewing whether you were giving up a discrimination claim.

Because Pfizer does substantial business with the federal government, insiders with knowledge of demographic employment practices during the certification period may also have information relevant to a False Claims Act qui tam claim — a mechanism that lets individuals bring claims on the government’s behalf and potentially share in any recovery. Qui tam complaints are filed under seal, so a whistleblower’s identity is initially protected. Both Title VII and the False Claims Act prohibit retaliation against people who assert their rights or report violations.

If any of these fits, it costs nothing to find out where you stand — meet our DEI discrimination lawyers, or start below.

What could a claim against Pfizer be worth?

Claims arising from practices like those documented at Pfizer Inc. can carry substantial value: False Claims Act whistleblowers receive 15–30% of any government recovery, individual discrimination cases combine uncapped lost pay with damages that several statutes leave uncapped, and a single companywide policy can support a class action. The figures below are illustrative — not a prediction for any individual case.

Whistleblower rewards under the False Claims Act

Under 31 U.S.C. § 3730(d), a qui tam whistleblower (called a “relator”) is entitled to 15–25% of what the government recovers when the Justice Department intervenes, and 25–30% when the relator litigates without government intervention. For scale: on a settlement the size of IBM’s $17,077,043, the intervened-case whistleblower share would be roughly $2.6 million to $4.3 million. Because False Claims Act recoveries are built on treble damages plus per-claim penalties, recoveries against very large contractors can run substantially higher.

Damages in individual discrimination cases

Back pay and front pay are uncapped under Title VII. Compensatory and punitive damages under Title VII are capped by employer size — $300,000 for employers with more than 500 employees, the bracket Pfizer occupies — but race claims under 42 U.S.C. § 1981 carry no damages caps at all, which is one reason race discrimination cases are often pleaded under it, and many state civil-rights statutes (including Michigan’s Elliott-Larsen Civil Rights Act) are likewise uncapped. Prevailing plaintiffs generally recover attorney’s fees on top. For a sense of what employment discrimination cases can produce, Fett Law’s own results include a $10.5 million race and age discrimination class action against Ford Motor Company, a $2 million disability harassment result, and a $1.6 million racial harassment result. Prior results do not guarantee a similar outcome.

Class action potential

Class actions are built on a single policy applied to many people — and the practices documented above are companywide by design: one slate requirement covering every U.S. job requisition, one scorecard covering more than 40,000 colleagues, one set of published representation targets. Historic employment-discrimination class settlements show what such cases can reach: Coca-Cola paid $192.5 million (2000), Texaco $176.1 million (1996), and Novartis $175 million (2010) to resolve class claims.

Every case depends on its own facts — these figures show the range the law makes possible, not a promise of any outcome. The fastest way to learn where your situation falls is to start a confidential intake or request a free consultation.

Frequently asked questions

Sources

Pfizer documents below were retrieved and verified in August 2026. Page citations refer to the PDF as published.

• Pfizer, Environmental, Social & Governance Report 2020 (published March 10, 2021), pp. 10, 22 — no longer available at its original pfizer.com address; archived copy (ResponsibilityReports) · UN Global Compact copy
• Pfizer, 2021 ESG Report, p. 23 (“Refreshing Our DEI Strategy”) — PDF
• Pfizer, 2021 Annual Review (Breakthrough Fellowship Program) — PDF
• Pfizer, Environmental, Social & Governance Report Pfizer 2022, p. 47 (ESG Scorecard) — PDF
• Pfizer, 2023 Impact Report, p. 23 (“Right Incentives”) and the “Opportunity Parity” section — PDF; companion 2023 ESG Performance data file — PDF
• Pfizer, 2024 Impact Report (“Equity for Colleagues”; merit-based talent approach) — PDF
• Pfizer, 2025 Impact Report — PDF
• Covington & Burling LLP, A Report to Pfizer Inc. On Its Efforts To Promote Racial Equity, Diversity, and Inclusion (March 2024), pp. 14–16 — PDF
• Pfizer, consolidated EEO-1 Reports 2016–2024 (posted May 30, 2025) — PDF
• Pfizer, “Merit-Based Diversity, Equity, and Inclusion: Who We Are” — current page; STAT News, “Pfizer revises its DEI webpage to emphasize importance of ‘merit’” (Feb. 27, 2025) — article
• Do No Harm v. Pfizer, Inc., No. 23-15 (2d Cir. Jan. 10, 2025) — opinion; plaintiff’s case page and January 31, 2025 stipulation announcement — Do No Harm
• Pfizer, “Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses” (July 22, 2020) — press release
• U.S. Department of Justice, “IBM Pays $17 Million to Resolve Allegations of Discrimination Through Illegal DEI Practices” (Apr. 10, 2026) — press release
• Executive Order 14173, “Ending Illegal Discrimination and Restoring Merit-Based Opportunity” (Jan. 21, 2025), 90 FR 8633 — Federal Register
• Title VII, 42 U.S.C. § 2000e-2 — statute; 42 U.S.C. § 1981 — statute; False Claims Act, 31 U.S.C. §§ 3729–3733 — statute; Muldrow v. City of St. Louis (2024) — opinion; Ames v. Ohio Dep’t of Youth Services (2025) — opinion